Amubarvimab
Based on 1 publication(s) in Google Scholar
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants.
For research use only. We do not sell to patients.
- Purity : 95.00%
- CAS No.: 2509447-07-6
- Molecular Weight:143.84 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
Severe acute respiratory syndrome coronavirus 2
In Vitro
Amubarvimab shows specific activity against wild-type SARS-CoV-2 and no cross-reactivity against other coronaviruses[1].
Amubarvimab binds to two regions spanning amino acids 453-505 in the receptor-binding motif (RBM) and amino acids residues 403-421 in the core region of RBD[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Product Details
-
CAS No. 2509447-07-6
-
Accession P59594
-
Synonyms BRII-196
-
Molecular Weight 143.84 kDa
-
Species Reactivity
Virus
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
95.00%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Emerg Microbes Infect
Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains. [Abstract]2026 Dec;15(1):2686472. PMID: 42324717
Purity & Documentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. [Content Brief]
[2]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82(12):1327-1331. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)